African Trypanosomiasis - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

African Trypanosomiasis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'African Trypanosomiasis - Pipeline Review, H2 2016', provides an overview of the African Trypanosomiasis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for African Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of African Trypanosomiasis
- The report reviews pipeline therapeutics for African Trypanosomiasis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved African Trypanosomiasis therapeutics and enlists all their major and minor projects
- The report assesses African Trypanosomiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for African Trypanosomiasis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for African Trypanosomiasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding African Trypanosomiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table Of Content

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
African Trypanosomiasis Overview 7
Therapeutics Development 8
Pipeline Products for African Trypanosomiasis - Overview 8
Pipeline Products for African Trypanosomiasis - Comparative Analysis 9
African Trypanosomiasis - Therapeutics under Development by Companies 10
African Trypanosomiasis - Therapeutics under Investigation by Universities/Institutes 11
African Trypanosomiasis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
African Trypanosomiasis - Products under Development by Companies 15
African Trypanosomiasis - Products under Investigation by Universities/Institutes 16
African Trypanosomiasis - Companies Involved in Therapeutics Development 17
Novartis AG 17
Sanofi 18
Scynexis, Inc. 19
African Trypanosomiasis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 26
Drug Profiles 28
AN-5568 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
DDD-100097 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
fexinidazole - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
GNF-6702 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
melarsoprol hydroxypropylbetadex - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Peptides for Sleeping Sickness - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecules for African Trypanosomiasis - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules for African Trypanosomiasis and Infectious Diseases - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules for Infectious Diseases - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules for Protozoal Infections - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecules for Sleeping Sickness - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecules to Inhibit Leucyl-tRNA Synthetase (LeuRS) for Human African Trypanosomiasis - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecules to Inhibit N-Myristoyltransferase for African Trypanosomiasis - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
African Trypanosomiasis - Dormant Projects 43
African Trypanosomiasis - Discontinued Products 44
African Trypanosomiasis - Product Development Milestones 45
Featured News & Press Releases 45
Sep 08, 2015: Clinical trial for first oral drug candidate specifically developed for sleeping sickness 45
Mar 12, 2012: Anacor Announces Commencement Of Phase I Clinical Trials Of Boron-Based Compound For Sleeping Sickness 45
Jun 28, 2011: Anacor Pharmaceuticals Partnership Advances New Drug Candidate To Combat Sleeping Sickness 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List Of Tables

Number of Products under Development for African Trypanosomiasis, H2 2016 8
Number of Products under Development for African Trypanosomiasis - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
African Trypanosomiasis - Pipeline by Novartis AG, H2 2016 17
African Trypanosomiasis - Pipeline by Sanofi, H2 2016 18
African Trypanosomiasis - Pipeline by Scynexis, Inc., H2 2016 19
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Stage and Target, H2 2016 22
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27
African Trypanosomiasis - Dormant Projects, H2 2016 43
African Trypanosomiasis - Discontinued Products, H2 2016 44